Literature DB >> 8841717

Direct cochlear nerve action potentials as an aid to hearing preservation in middle fossa acoustic neuroma resection.

J Roberson1, A Senne, D Brackmann, W E Hitselberger, J Saunders.   

Abstract

A new application of auditory evoked potentials using direct cochlear nerve action potentials (CNAPs) for monitoring middle fossa acoustic neuroma resection with attempted hearing preservation is described. Twenty patients have been studied to date. With this technique, a monitoring electrode is secured between the floor of the internal auditory canal and the dura adjacent to the cochlear nerve in an extradural location. Standard auditory evoked potential techniques with click stimuli and microelectrical recording allow observation of nearfield waveforms in seconds versus several minutes required for farfield potentials recorded from the scalp. Advantages of this technique over auditory brainstem response monitoring may include nearly real time measurement of potentials, improved surgeon learning curve and possibly higher rates of hearing preservation, and applicability to all patients undergoing hearing-preservation surgery independent of presence or absence of ABR tracing. Immediate changes in amplitude and latency of waveforms appear to compare with reversible and irreversible intraoperative auditory system damage, thereby guiding surgical maneuvers.

Entities:  

Mesh:

Year:  1996        PMID: 8841717

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  2 in total

1.  Association between surgical steps and intraoperative auditory brainstem response and electrocochleography waveforms during hearing preservation vestibular schwannoma surgery.

Authors:  Haralampos Gouveris; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06-14       Impact factor: 2.503

2.  ASNM position statement: intraoperative monitoring of auditory evoked potentials.

Authors:  William Hal Martin; Mark M Stecker
Journal:  J Clin Monit Comput       Date:  2008-02       Impact factor: 1.977

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.